Furthermore, while activation of the LXR/RXR activation pathway by Ex-4 in our model does not reconcile with steatosis reduction in in vivo studies, GLP-1R agonists may employ this pathway to reduce hepatic inflammation and so alleviate NAFLD. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.